新股暗盘 | 昭衍新药(6127.HK)暗盘段跌5%
格隆汇2月25日丨据辉立证券,昭衍新药(6127.HK)暗盘段现报143.3港元,较发行价151港元跌5%。公司是一家专注于药物非临床安全性评价的领先合同研究组织,2017年至2019年收益分别为3.01亿、4.08亿、6.39亿元人民币,溢利分别为7991.7万、1.05亿、1.87亿元人民币,每股有形资产净值23.82-26.61港元。此次上市全球发售4332.48万股,其中香港发售1559.7万股,国际发售2772.78万股,每手100股,一手中签率5%,香港公开发售获310倍认购,净筹62.861亿港元,中国结构调整基金等多家基石投资者已合共认购1375.98万股,占完成后公司已发行股本约5.1%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.